IRIS
VIOLA, Anna
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.470
NA - Nord America 1.723
AS - Asia 1.329
SA - Sud America 386
AF - Africa 43
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 2
Totale 5.956
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.662
RU - Federazione Russa 1.459
SG - Singapore 621
BR - Brasile 325
CN - Cina 284
IE - Irlanda 242
IT - Italia 238
SE - Svezia 192
HK - Hong Kong 181
FR - Francia 79
VN - Vietnam 77
DE - Germania 76
IN - India 43
GB - Regno Unito 42
CA - Canada 31
PL - Polonia 29
FI - Finlandia 26
BD - Bangladesh 24
AT - Austria 22
AR - Argentina 21
NL - Olanda 20
MX - Messico 17
JP - Giappone 15
ZA - Sudafrica 11
EC - Ecuador 10
ES - Italia 9
TR - Turchia 9
CL - Cile 8
IQ - Iraq 8
PK - Pakistan 8
ID - Indonesia 7
KE - Kenya 7
UZ - Uzbekistan 7
JO - Giordania 6
PH - Filippine 6
VE - Venezuela 6
BE - Belgio 5
CO - Colombia 5
LT - Lituania 5
MA - Marocco 5
MY - Malesia 5
NI - Nicaragua 5
PY - Paraguay 5
SA - Arabia Saudita 5
KZ - Kazakistan 4
NO - Norvegia 4
PE - Perù 4
TN - Tunisia 4
AE - Emirati Arabi Uniti 3
AO - Angola 3
CH - Svizzera 3
CZ - Repubblica Ceca 3
DO - Repubblica Dominicana 3
DZ - Algeria 3
ET - Etiopia 3
UA - Ucraina 3
AL - Albania 2
AZ - Azerbaigian 2
BY - Bielorussia 2
EE - Estonia 2
GE - Georgia 2
GT - Guatemala 2
IL - Israele 2
NP - Nepal 2
NZ - Nuova Zelanda 2
PS - Palestinian Territory 2
RO - Romania 2
RS - Serbia 2
SN - Senegal 2
SY - Repubblica araba siriana 2
UY - Uruguay 2
AU - Australia 1
BG - Bulgaria 1
BW - Botswana 1
CR - Costa Rica 1
EG - Egitto 1
EU - Europa 1
GR - Grecia 1
HU - Ungheria 1
IR - Iran 1
KW - Kuwait 1
LK - Sri Lanka 1
LY - Libia 1
RE - Reunion 1
SC - Seychelles 1
SV - El Salvador 1
TT - Trinidad e Tobago 1
TW - Taiwan 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 5.956
Salva come PNG Salva come JPEG
Città #
Moscow 450
Ashburn 370
Singapore 310
Dublin 240
San Jose 184
Hong Kong 181
Chandler 169
Dallas 139
Nyköping 94
Beijing 73
Messina 60
Los Angeles 51
Lauterbourg 39
The Dalles 38
Princeton 37
Medford 33
Munich 31
São Paulo 27
Des Moines 24
Hanoi 24
New York 22
Ho Chi Minh City 21
Frankfurt am Main 20
Orem 20
Redondo Beach 20
Buffalo 19
Chennai 18
Council Bluffs 16
Santa Clara 15
Seattle 15
Vienna 15
Catania 14
London 14
Tokyo 14
Ann Arbor 13
Milan 13
Denver 12
Warsaw 12
Amsterdam 11
Atlanta 11
Rome 11
Stockholm 11
Brooklyn 10
Guangzhou 10
Mexico City 10
Nuremberg 10
Jinan 9
Lappeenranta 9
Curitiba 8
Jacksonville 8
Montreal 8
Rio de Janeiro 8
Tianjin 8
Dearborn 7
Manchester 7
Porto Alegre 7
Shanghai 7
Turku 7
Amman 6
Boston 6
Campinas 6
Changsha 6
Chicago 6
Johannesburg 6
Mumbai 6
Nairobi 6
Nanjing 6
Pozzuolo Martesana 6
San Francisco 6
Shenzhen 6
Tashkent 6
Toronto 6
Turin 6
Wilmington 6
Belo Horizonte 5
Brussels 5
Düsseldorf 5
Hebei 5
Helsinki 5
Houston 5
Jakarta 5
Lahore 5
Managua 5
Palermo 5
Phoenix 5
Zhengzhou 5
Baghdad 4
Brasília 4
Cagliari 4
Guayaquil 4
Haikou 4
Hangzhou 4
Pelotas 4
Pune 4
Santiago 4
Shenyang 4
Vitória da Conquista 4
Addis Ababa 3
Aracaju 3
Bexley 3
Totale 3.253
Salva come PNG Salva come JPEG
Nome #
Diagnostic accuracy of faecal calprotectin in a symptom-based algorithm for early diagnosis of inflammatory bowel disease adjusting for differential verification bias using a Bayesian approach 207
Effectiveness and Safety Profiles of Biological Therapies in Inflammatory Bowel Disease: Real Life Data from an Active Pharmacovigilance Project 169
Cancer risk in inflammatory bowel disease: a 6-year prospective multicenter nested case-control IG-IBD study 166
Comparative Efficacy of Vedolizumab and Adalimumab in Ulcerative Colitis Patients Previously Treated With Infliximab 157
DWI ratios: New indexes for Crohn's disease activity at magnetic resonance enterography? 155
Direct oral anticoagulants increase the risk of anaemia and hospitalization in IBD patients with active intestinal disease 154
Outcome in ulcerative colitis after switch from adalimumab/golimumab to infliximab: A multicenter retrospective study 151
Effectiveness of Ustekinumab on Crohn‘s Disease Associated Spondyloarthropathy: Real-World Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD) 151
A propensity score weighted comparison of Vedolizumab, Adalimumab, and Golimumab in patients with ulcerative colitis 146
Late-onset Crohn's disease: a comparison of disease behaviour and therapy with younger adult patients: the Italian Group for the Study of Inflammatory Bowel Disease 'AGED' study 144
Dual Targeted Therapy: a possible option for the management of refractory Inflammatory Bowel Disease 144
Disease patterns in late-onset ulcerative colitis: Results from the IG-IBD “AGED study” 141
Role of IL-33/ST2 Pathway in Inflammatory Bowel Disease: An Overview and Future Perspectives 139
Effectiveness and safety of vedolizumab in biologically naïve patients: A real-world multi-centre study 139
Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: The IG-IBD LIVE study 133
Quality of Life (QoL) in Patients with Chronic Inflammatory Bowel Diseases: How Much Better with Biological Drugs? 120
Inflammatory Bowel Disease in the Elderly – Knowledge Gaps and Potential Directions in Research 115
A propensity score weighted comparison of vedolizumab and adalimumab in Crohn's disease 114
Comparison of two strategies for the management of postoperative recurrence in Crohn's disease patients with one clinical risk factor: A multicentre IG-IBD study 113
Prevalence, Pathogenesis and Management of Anemia in Inflammatory Bowel Disease: An IG-IBD Multicenter, Prospective, and Observational Study 111
Tissue levels of Tumour Necrosis Factor-alpha as molecular biomarker of inflammation and prediction of sustained treatment response in patients with Ulcerative Colitis. 109
A real world investigation on prevalence, clinical features, and therapy of inflammatory bowel disease in the city of Messina, Italy 108
Management of patients with inflammatory bowel disease and outcomes during the first wave of the Covid-19 pandemic 108
The SPOSIB SB2 Sicilian Cohort: Safety and Effectiveness of Infliximab Biosimilar SB2 in Inflammatory Bowel Diseases, Including Multiple Switches 106
Effectiveness of adalimumab for ulcerative colitis: A multicentre, retrospective study of clinical practice in Italy 103
Ustekinumab in Crohn's disease: Real-world outcomes from the Sicilian network for inflammatory bowel diseases 100
Stevens-Johnson syndrome on treatment with sulfasalazine for Crohn’s disease: Need for a multidisciplinary approach 97
Defense mechanisms and inflammatory bowel diseases: a narrative review 96
One-year effectiveness and safety of ustekinumab in ulcerative colitis: a multicenter real-world study from Italy 94
IL PAZIENTE ANZIANO CON MALATTIA INFIAMMATORIA CRONICA INTESTINALE: OSSERVAZIONI IN UN GRUPPO DI PAZIENTI AMBULATORIALI 93
Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of care 92
DWI ratios at MR-Enterography: a new way for inflammation degree assessment in Crohn's disease patients? 92
The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar 92
Efficacy and Safety of Biological Therapies and JAK Inhibitors in Older Patients with Inflammatory Bowel Disease 91
Telemedicine and Remote Screening for COVID-19 in Inflammatory Bowel Disease Patients: Results from the SoCOVID-19 Survey 90
Genetic Polymorphisms on TNFA, TNFRSF1A, and TNFRSF1B Genes Predict the Effectiveness of Anti-TNF-α Treatment in Inflammatory Bowel Disease Patients 88
Objective comparison of vedolizumab and ustekinumab effectiveness in Crohn's disease patients failure to TNF-alpha inhibitors 86
Persistence on Anti-Tumour Necrosis Factor Therapy in Older Patients with Inflammatory Bowel Disease Compared with Younger Patients: Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD) 86
Rates of Adverse Events in Patients With Ulcerative Colitis Undergoing Colectomy During Treatment With Tofacitinib vs Biologics: A Multicenter Observational Study 85
Predictors of Covid-19 vaccination acceptance in IBD patients: a prospective study 83
Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune-mediated inflammatory diseases: A European retrospective observational study 81
Portal hypertensive enteropathy: multimodality assessment through computed tomography and magnetic resonance enterography 80
Mitigating the Risk of Tofacitinib-induced Adverse Events in the Elderly Population with Ulcerative Colitis 78
Ultrasonography tight control and monitoring in crohn's disease during different biological therapies: a multicenter study 73
Low Adherence is Associated with Chronic Active Disease in Ulcerative Colitis: A Retrospective Study from a Single Referral Center 72
Follow-up evaluation and management of anemia in inflammatory bowel disease: A study by the Italian Group for Inflammatory Bowel Diseases (IG-IBD) 68
Upadacitinib-Induced Hemolysis in a Patient With Glucose-6-Phosphate Dehydrogenase Deficiency-A Possible Adverse Drug Reaction 67
Corticosteroid use in patients with inflammatory bowel diseases: A real-life sub-analysis of the Italian DICE study 65
Two-year effectiveness and safety of golimumab in ulcerative colitis: An IG-IBD study 62
Epidemiology and clinical course of late onset inflammatory bowel disease 61
Incident Colorectal Cancer in Inflammatory Bowel Disease 59
Ménétrier's disease in a patient with refractory ulcerative colitis: a clinical challenge and review of the literature 55
SPOSAB ABP 501 - A Sicilian Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Adalimumab Biosimilar ABP 501 52
Letter: the clinical course of Crohn's disease—the Sicilian experience 46
Vedolizumab may be an effective option for the treatment of postoperative recurrence of Crohn's disease 45
Safety and effectiveness of tofacitinib in ulcerative colitis: Data from TOFA-UC, a SN-IBD study 41
null 40
Cardiovascular Risk Assessments and Ultrasound-Assisted Re-Stratification in Patients with Inflammatory Bowel Disease (IBD) 39
Ustekinumab is a promising option for the treatment of postoperative recurrence of Crohn's disease 36
Standard Therapeutic Approach and New Therapies 35
null 33
Psychological impairment in inflammatory bowel diseases: the key role of coping and defense mechanisms 33
Ulcerative Colitis in Adulthood and in Older Patients: Same Disease, Same Outcome, Same Risks? 32
Suboptimal disease control and contributing factors in Italian IBD patients: The IBD-PODCAST Study 30
TNF-α Quantification in Formalin-Fixed Paraffin-Embedded Tissues as a Predictive Biomarker in Ulcerative Colitis 26
Severe Activity of Inflammatory Bowel Disease is a Risk Factor for Severe COVID-19 25
The Effectiveness of Risankizumab as Induction Therapy for Crohn's Disease: Data From the Sicilian Network for Inflammatory Bowel Diseases 24
Vedolizumab in inflammatory bowel disease: Real-world outcomes and their prediction with machine learning-the IG-IBD LIVE study 15
Managing Acute Severe Ulcerative Colitis in the Older Patient: A Growing Concern 4
Totale 6.145
Salva come PNG Salva come JPEG
Categoria #
all - tutte 21.780
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 21.780
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20217 0 0 0 0 0 0 0 0 0 0 0 7
2021/2022287 5 31 3 2 8 4 14 10 11 74 21 104
2022/2023597 39 65 26 53 29 45 14 28 268 11 13 6
2023/2024256 20 29 36 54 14 23 7 15 0 33 8 17
2024/20251.244 16 21 16 79 60 76 94 194 271 79 133 205
2025/20263.542 156 145 216 227 339 745 474 490 437 188 65 60
Totale 6.145